Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. Design: Cross-sectional survey. Setting: Community. Participants: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. Measurements: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). Results: There were 72 hypertensive participants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensive participants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. Conclusion: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensive patients on ACEIs.

Original languageEnglish (US)
JournalJournal of the American Medical Directors Association
DOIs
StateAccepted/In press - 2016

Fingerprint

Gait
Angiotensin-Converting Enzyme Inhibitors
Independent Living
Antihypertensive Agents
Linear Models
Cross-Sectional Studies
Regression Analysis
Hypertension

Keywords

  • Ace inhibitors
  • Gait
  • Physical performance

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Health Policy

Cite this

@article{14d9cfba0bfd4fb888a7e3d96421d4c1,
title = "Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors",
abstract = "Objective: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. Design: Cross-sectional survey. Setting: Community. Participants: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. Measurements: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). Results: There were 72 hypertensive participants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensive participants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. Conclusion: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensive patients on ACEIs.",
keywords = "Ace inhibitors, Gait, Physical performance",
author = "George, {Claudene J.} and Joe Verghese",
year = "2016",
doi = "10.1016/j.jamda.2016.03.022",
language = "English (US)",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors

AU - George, Claudene J.

AU - Verghese, Joe

PY - 2016

Y1 - 2016

N2 - Objective: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. Design: Cross-sectional survey. Setting: Community. Participants: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. Measurements: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). Results: There were 72 hypertensive participants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensive participants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. Conclusion: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensive patients on ACEIs.

AB - Objective: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. Design: Cross-sectional survey. Setting: Community. Participants: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. Measurements: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). Results: There were 72 hypertensive participants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensive participants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. Conclusion: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensive patients on ACEIs.

KW - Ace inhibitors

KW - Gait

KW - Physical performance

UR - http://www.scopus.com/inward/record.url?scp=84969220167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969220167&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2016.03.022

DO - 10.1016/j.jamda.2016.03.022

M3 - Article

C2 - 27209273

AN - SCOPUS:84969220167

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

ER -